Tag: Nasdaq:HCM

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 02, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) announced that the U.S. Food and ...

HONG KONG, and SHANGHAI, China and FLORHAM PARK, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; SEHK:13) provides an update on its status ...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 11, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; SEHK:13) would like to provide an ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has received a US$15 million milestone payment from AstraZeneca ...

HONG KONG and FLORHAM PARK, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has received approval to market fruquintinib (ELUNATE® in ...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 04, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase Ib/II ...

HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase I trial in ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that updated analysis of the ongoing ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the Center for Drug Evaluation of China’s ...

— HMPL-760 is the eleventh innovative potential oncology drug candidate discovered in-house by HUTCHMED — — HMPL-760 is HUTCHMED’s fifth candidate in clinical development for hematological malignancies, including amdizalisib and HMPL-523 that ...